McKinsey & Company Skip main navigation

Pharmaceuticals & Medical Products

We work with leading innovators in pharmaceuticals and medical products to ask the right questions, provide insights, and deliver results. We help clients build capabilities to deliver lasting business impact.

Our expertise

Proprietary tools & solutions

Our sophisticated tools and solutions help pharmaceutical and medical product companies during the entire product development lifecycle, from discovery through post-launch. Many were created specifically to address the unique challenges that PMP companies confront.more

Latest thinking

Beyond the storm
compendium

Beyond the storm: Launch in the new normal

Only a third of launches meet or exceed analysts’ expectations. What should pharma companies do to deliver excellence at launch?

Personalized medicine
compendium

Personalized medicine: The path forward

Personalized medicine is now poised for rapid growth because of recent scientific advances. With the right strategies, pharmacos, biotechs, and diagnostic companies could capture many new opportunities in this surging field.

Developing capabilities in supply chain, Marketing, R&D
compendium

Unlocking pharma growth : Navigating the intricacies of emerging markets

Emerging markets offer attractive opportunities for growth, but pharma companies need to navigate the intricacies of individual markets and develop tailored capabilities and commercial models to tackle the challenges.

Healthcare challenges in China
compendium | McKinsey Greater China

Healthcare in China: Entering uncharted waters

China’s healthcare sector continues to develop at an astonishing rate, but challenges remain. McKinsey’s Healthcare Practice in China has published a new report which offers a diversity of perspectives on this substantial, complex and important domain. A selection of articles are published on the McKinsey China Healthcare page.

Operations for the executive suite
compendium

Operations for the executive suite

Highlights specific opportunities for operations to create significant value upside for pharmacos and emphasizes the role of the executive suite in enabling this value creation

Escaping the sword of Damocles
compendium

Evolution or Revolution: McKinsey perspective on drug and device R&D

Recent years have seen a collapse in the industry’s R&D productivity. Regaining trust by delivering life-changing new drugs is still an achievable goal, but it will require discipline, creativity, and luck in equal measure.

Death of a sales model, or not
compendium

Death of a sales model, or not

Discusses how pharmaceutical companies will need to adjust their traditional sales models to suit the evolving healthcare landscape

Contact

Meet our people

Michael Silber

Michael Silber

Director
Vivian Hunt

Vivian Hunt

Director
Rajesh Parekh

Rajesh Parekh

Director
More profiles

Featured insights

articlehobi13_frth_Thumbnail

How big data can revolutionize pharmaceutical R&D

April 2013—Pharmaceutical R&D suffers from declining success rates and a stagnant pipeline. Big data and the analytics that go with it could be a key element of the cure.more

  • includes:
    •